The Zhitong Finance App learned that Conoa-B (02162) rose more than 5%. As of press release, it had risen 5.06% to HK$80.95, with a turnover of HK$82.7412 million.

According to the news, Conoa-B issued an announcement. On August 19, 2026, the Board of Directors of the Company decided that the Company proposes to issue common shares listed on the Shanghai Stock Exchange Science and Technology Innovation Board (Science and Technology Innovation Board) and traded in RMB (it is recommended to issue RMB shares). The proposed issuance of RMB shares is subject to (including) market conditions, further approval by the board of directors, approval by the Company's shareholders at the Company's shareholders' meeting and obtaining the necessary regulatory approval.

Earlier, Conoa-B released a profit forecast. The company expects to make a profit of no less than RMB 1.2 billion in the first half of 2026. The company's innovative product Kangyueda ^® has outstanding clinical value, and the number of patients covered continues to increase. The first half of 2026 achieved sales revenue of 390 million yuan, an increase of 132% over the previous year, providing the company with continuous revenue.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.